droperidol (innovar) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Droperidol produces marked tranquilization and sedation. It allays apprehension and provides a state of mental detachment and indifference while maintaining a state of reflex alertness. Droperidol produces an antiemetic effect as evidenced by the antagonism of apomorphine in dogs. It lowers the incidence of nausea and vomiting during surgical procedures and provides antiemetic protection in the postoperative period. Droperidol potentiates other CNS depressants. It produces mild alpha-adrenergic blockade, peripheral vascular dilatation and reduction of the pressor effect of epinephrine. It can produce hypotension and decreased peripheral vascular resistance and may decrease pulmonary arterial pressure (particularly if it is abnormally high). It may reduce the incidence of epinephrine-induced arrhythmias, but it does not prevent other cardiac arrhythmias. The exact mechanism of action is unknown, however, droperidol causes a CNS depression at subcortical levels of the brain, midbrain, and brainstem reticular formation. It may antagonize the actions of glutamic acid within the extrapyramidal system. It may also inhibit cathecolamine receptors and the reuptake of neurotransmiters and has strong central antidopaminergic action and weak central anticholinergic action. It can also produce ganglionic blockade and reduced affective response. The main actions seem to stem from its potent Dopamine (2) receptor antagonism with minor antagonistic effects on alpha-1 adrenergic receptors as well. Droperidol is used to produce tranquilization and to reduce the incidence of nausea and vomiting in surgical and diagnostic procedures.   NCATS

Chemistry

  • SMILES: FC1=CC=C(C=C1)C(=O)CCCN2CCC(=CC2)N3C(=O)NC4=C3C=CC=C4
  • InChIKey: RMEDXOLNCUSCGS-UHFFFAOYSA-N
  • Mol. Mass: 379.4274
  • ALogP: 3.68
  • ChEMBL Molecules:
    droperidol  
    None  
More Chemistry

Pharmacology

Combination drugs

( fentanyl (Innovar), droperidol (innovar) )

Alternative names

1-(1-(3-(p-fluorobenzoyl)propyl)-1,2,3,6-tetrahydro-4-pyridyl)-2-benzimidazolinone | 1-{1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydro-4-pyridinyl}-2,3-dihydro-1h-benzo[d]imidazol-2-one | 1-{1-[4-(4-fluoro-phenyl)-4-oxo-butyl]-1,2,3,6-tetrahydro-pyridin-4-yl}-1,3-dihydro-benzoimidazol-2-one | 1-(1-(4-(p-fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydro-4-pyridyl)-2-benzimidazolinone | dehydrobenzperidol | dridol | droleptan | droperidol | dropéridol | droperidolo | droperidolum | inapsin | inapsine | mcn-jr-4749 | neurolidol | r-4749

Organizations (43)

Research & Development (28)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (15)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (25)

Approved Indications (1)


 

Postoperative Nausea and Vomiting (approved 1970)

Experimental Indications - Clinical Trial Phases 1-4 (25)


 

Arthropathy, Neurogenic (Phase 4)

Cannabis (Phase 3)

Cholecystolithiasis (Phase 4)

Colonic Neoplasms (Phase 4)

Dental Care for Disabled (Phase 4)

Drug Interactions (Phase 3)

Fractures, Bone (Phase 4)

Genital Neoplasms, Female (Phase 4)

Hallux Valgus (Phase 4)

Heart Diseases (Phase 4)

Hernia, Inguinal (Phase 4)

Kidney Neoplasms (Phase 4)

Liver Neoplasms (Phase 4)

Mental Health (Phase 3)

Nausea (Phase 4)

Pain (Phase 3)

Pain, Postoperative (Phase 4)

Postoperative Nausea and Vomiting (Phase 4)

Prostatic Neoplasms (Phase 4)

Psychomotor Agitation (Phase 3)

Rectal Neoplasms (Phase 4)

Sigmoid Neoplasms (Phase 4)

Stomach Neoplasms (Phase 4)

Urinary Bladder Neoplasms (Phase 4)

Vomiting (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 26
  • # of Trial Organizations: 28

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue